ABCELLERA BIOLOGICS INC's ticker is ABCL and the CUSIP is 00288U106. A total of 115 filers reported holding ABCELLERA BIOLOGICS INC in Q2 2021. The put-call ratio across all filers is 0.62 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,358,238 | -28.8% | 3,773,530 | 0.0% | 89.37% | -2.2% |
| Q2 2023 | $24,377,004 | -14.3% | 3,773,530 | 0.0% | 91.35% | +0.2% |
| Q1 2023 | $28,452,416 | -25.6% | 3,773,530 | 0.0% | 91.13% | -3.5% |
| Q4 2022 | $38,225,859 | +2.4% | 3,773,530 | 0.0% | 94.47% | +2.0% |
| Q3 2022 | $37,320,000 | -7.1% | 3,773,530 | 0.0% | 92.58% | -0.5% |
| Q2 2022 | $40,188,000 | +9.2% | 3,773,530 | 0.0% | 93.02% | +2.1% |
| Q1 2022 | $36,791,000 | -31.8% | 3,773,530 | 0.0% | 91.10% | +1.5% |
| Q4 2021 | $53,961,000 | -28.6% | 3,773,530 | 0.0% | 89.75% | +4.2% |
| Q3 2021 | $75,584,000 | -9.0% | 3,773,530 | 0.0% | 86.10% | +8.2% |
| Q2 2021 | $83,018,000 | -35.2% | 3,773,530 | 0.0% | 79.60% | -7.6% |
| Q1 2021 | $128,149,000 | -15.6% | 3,773,530 | 0.0% | 86.19% | +1.3% |
| Q4 2020 | $151,847,000 | – | 3,773,530 | – | 85.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Founders Fund VII Management, LLC | 3,773,530 | $17,358,238 | 89.37% |
| Founders Fund Growth Management, LLC | 407,017 | $1,872,278 | 5.10% |
| Prosight Management, LP | 2,446,000 | $11,251,600 | 3.57% |
| Intellectus Partners, LLC | 876,633 | $4,032,511 | 1.28% |
| Belmont Capital, LLC | 510,000 | $2,346,000 | 1.27% |
| Casdin Capital, LLC | 2,360,129 | $10,856,593 | 1.20% |
| GUARDIAN CAPITAL ADVISORS LP | 1,786,414 | $7,842,357 | 0.88% |
| Baker Brothers Advisors | 20,763,323 | $95,511,286 | 0.55% |
| BRANDYWINE MANAGERS, LLC | 56,976 | $262,090 | 0.44% |
| Orbimed Advisors | 4,180,768 | $19,231,533 | 0.41% |